Obbligazioni societarie HIGH YIELD e oltre, verso frontiere inesplorate - Vol. 2

[marcob77]

scusate, volevo comprare un lotto della jaguar 2026. c'è scritto che è garantita da due società del gruppo tata motors... in realtà il titolo è garantito da jaguar land rover limited e jaguar land rover holding. Quest'ultima è di proprietà del 100% di TML Holdings PTE Limited (Singapore) la quale a sua volta è di proprietà di Tata motors Limited... Secondo voi tutte queste scatole aumentano i rischi sul bond oppure Tata motors garantisce per il bond? (io penso di no...)

https://dl.bourse.lu/dl?v=ADyMFy5zx...liVsH9v+wa42el7BoPxeGJvsIZAQZOOfBY8nO0NIYlg==

 

[NoWay]

Gentile Maurizio,

in relazione all’evento SEARS HOLDINGS CORP 2011 2018 6 625
USD Richiesta di consenso (isin US812350AE65), La informiamo
che, in data 15/10/2019, la “United States Bankruptcy Court
for the Southern District of New York” ha approvato il piano
di riorganizzazione.

 

[captain sparrow]

Schoeller Packaging emballe le marché avec sa nouvelle obligation à haut rendement | OBLIS

 

[angy2008]

scusate, volevo comprare un lotto della jaguar 2026. c'è scritto che è garantita da due società del gruppo tata motors... in realtà il titolo è garantito da jaguar land rover limited e jaguar land rover holding. Quest'ultima è di proprietà del 100% di TML Holdings PTE Limited (Singapore) la quale a sua volta è di proprietà di Tata motors Limited... Secondo voi tutte queste scatole aumentano i rischi sul bond oppure Tata motors garantisce per il bond? (io penso di no...)

https://dl.bourse.lu/dl?v=ADyMFy5zx...liVsH9v+wa42el7BoPxeGJvsIZAQZOOfBY8nO0NIYlg==

io ho la Jaguar 2026 in € e non penso che sia garantita da Tata a cascata delle scatole cinesi, comunque la tengo

 

[veltroni]

io ho la Jaguar 2026 in € e non penso che sia garantita da Tata a cascata delle scatole cinesi, comunque la tengo

La ritengo un ottimo HY sono ben 2 marchi prestigiosi e di LandRovet in giro ne vedo tante e sono pure belle se poi si considera che sono in euro le tengo e se non fosse per il taglio accumulerei

 

[waltermasoni]

Buy area 83
6,15% Teva Pharmaceutical Fin.Co. BV (2036) - US88163VAD10 - Börse Berlin

 

[waltermasoni]

Fitch Assigns Nexi S.p.A. Unsecured Bond Final 'BB'; Withdraws Senior Secured Rating
25 OCT 2019 05:40 AM ET

 

[waltermasoni]

Teva Pharmaceutical Industries Ltd. Ratings Placed On CreditWatch Negative Following Opioid Settlement Framework

• 24-Oct-2019 17:21 EDT

View Analyst Contact Information

• Table of Contents
  

• Israel-headquartered global specialty and generic pharmaceutical manufacturer Teva Pharmaceutical Industries Ltd. recently announced a tentative framework to settle litigation claims related to opioid sales for $23 billion of products and $250 million of cash over 10 years.
• The cash cost of this settlement framework is uncertain, although we currently estimate the discounted cost as less than $2 billion and we believe the final agreement could require a higher cash contribution to satisfy a larger group of plaintiffs.
• We are placing our ratings on Teva on CreditWatch with negative implications, including our 'BB' long-term issuer credit and senior unsecured issue-level ratings.
• We will resolve the CreditWatch placements when we gain greater confidence as to whether the discounted cost will likely exceed $2 billion (our trigger for a lower rating).

NEW YORK (S&P Global Ratings) Oct. 24, 2019--S&P Global Ratings today took the rating actions listed above.

Our CreditWatch placements reflect the higher risk of a downgrade due to the significant cash cost from the proposed global settlement framework related to opioid litigation. The proposed settlement framework calls for Teva Pharmaceutical Industries Ltd. to provide up to approximately $23 billion of buprenorphine naloxone (sublingual tablets) and $250 million of cash, both over 10 years. We believe the final amount to settle all claims related to opioids is uncertain, but we estimate the tax-adjusted discounted cash liability of the proposed framework could total less than $2 billion, depending on the cost of supplying the buprenorphine naloxone and the actual demand in the U.S. for it. We estimate the annual cash cost to fulfill the proposed settlement framework will be in the $250 million-$400 million range.

We plan to resolve the CreditWatch placements when we have more certainty that the ultimate settlement to resolve the opioid claims will be more or less than about $2 billion. We could consider resolving the placements when Teva reports its reserve to account for its proposed settlement framework, if it materially exceeds $2 billion. Alternatively, we could consider resolving them when more plaintiffs agree to the proposed settlement agreement and we believe the ultimate liability will be less than roughly $2 billion. We expect this to occur in the next four to six months.

We will also evaluate the impact to our recovery ratings when a more concrete settlement agreement is known. We do not expect a lower senior unsecured rating, but we could consider revising the recovery rating if we believe the claim from a settlement would materially impair the recovery of lenders in a default scenario.

 

[waltermasoni]

Lebanon Ratings Placed On CreditWatch Negative On Increasing Financial And Monetary Risks

• 24-Oct-2019 16:08 EDT

View Analyst Contact Information

 

[marcob77]

Buy area 83
6,15% Teva Pharmaceutical Fin.Co. BV (2036) - US88163VAD10 - Börse Berlin

ma poi, a parte l'accordo di pagamento in USA, i conti come vanno?